StockNews.com Begins Coverage on Arcturus Therapeutics (NASDAQ:ARCT)

StockNews.com began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) in a research report released on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT opened at $15.39 on Thursday. Arcturus Therapeutics has a 12 month low of $11.70 and a 12 month high of $31.41. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.22. The business has a fifty day simple moving average of $18.23 and a 200-day simple moving average of $17.26.

Insider Activity

In other news, COO Pad Chivukula sold 5,000 shares of the company’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $16.07, for a total transaction of $80,350.00. Following the completion of the sale, the chief operating officer now directly owns 589,448 shares of the company’s stock, valued at $9,472,429.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 12.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Great West Life Assurance Co. Can acquired a new position in Arcturus Therapeutics during the third quarter valued at $27,000. Allspring Global Investments Holdings LLC raised its position in Arcturus Therapeutics by 58.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,825 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 673 shares during the period. BNP Paribas Arbitrage SA raised its position in Arcturus Therapeutics by 63.4% during the second quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 1,956 shares during the period. Point72 Middle East FZE acquired a new position in Arcturus Therapeutics during the fourth quarter valued at $79,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Arcturus Therapeutics by 18.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,793 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 882 shares during the period. 83.74% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

(Get Rating)

Arcturus Therapeutics Holdings, Inc develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm’s products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF.